Aerie To Acquire Dry Eye Disease-Focused Pharma Avizorex
Zacks Investment Research | Nov 18, 2019 09:31PM ET
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) signed an agreement to acquire privately-held Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to boost its dry eye disease pipeline. Aerie will pay $10 million upfront to Avizorex for the acquisition. Moreover, shareholders of Avizorex are eligible to receive additional payments related to certain clinical and regulatory milestones, plus royalties on net sales of approved products from the company’s development pipeline. The acquisition is expected to be completed by the end of 2019.
Avizorex has completed a phase IIa study on lead pipeline candidate, AVX-012, in patients with dry eye disease. Data from the study were positive and demonstrated the therapeutic potential of AVX-012 to treat signs and symptoms of dry eye. Aerie is planning to initiate a phase IIb study on the candidate in late 2020.
Shares of Aerie have plunged 47.3% so far this year against the industry ’s growth of 5.8%.
Notably, Aerie’s lead drug Rhopressa was approved by the FDA for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension and is already available in the United States. A regulatory application for the drug is under review in Europe. In September, the Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending its approval. A final decision is expected by the year-end. Upon approval, the drug will be available under the tradename of Rhokiinsa in Europe.
Aerie's second drug Rocklatan, a once-daily, quadruple-action, fixed-dose combination of Rhopressa and Pfizer's (NYSE:PFE) Xalatan, was approved by the FDA in March to lower the elevated IOP in patients with open-angle glaucoma or ocular hypertension.
Aerie plans to submit a marketing authorization application for Rocklatan in Europe following the potential approval of Rhokiinsa in the region.
Meanwhile, we note that though the glaucoma market holds potential, Aerie faces stiff competition from Novartis’ (NYSE:NVS) Simbrinza and Travtan, Allergan’s (NYSE:AGN) Lumigan, and other smaller biotechnology and pharmaceutical companies.
Apart from the commercial drugs, Aerie has two early-stage retinal programs in its pipeline — AR-13503 (Rho kinase and Protein kinase C inhibitor implant) and AR-1105 (dexamethasone steroid implant).
Get The News You Want
Aerie Pharmaceuticals, Inc. Price
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.